Alector Licenses AL050 Program to Roche's Genentech
MT Newswires Live
Oct 05
Alector (ALEC) said Monday it entered an exclusive global licensing agreement with Genentech, a Roche firm, for the development and commercialization of its AL050 program targeting Parkinson's disease.
Under the deal, Alector said it will receive $100 million upfront and is eligible for up to $1.17 billion in development, regulatory and commercial milestones, as well as tiered royalties on net sales.
Genentech will handle development, regulatory, manufacturing and commercialization globally, the company.
Alector said it will retain ownership of its antibody blood-brain-barrier transport platform and rights to use it across its wholly owned pipeline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.